Kevin C. Knightly Sells 19,339 Shares of Quintiles Transitional Holdings Inc. (Q) Stock
Quintiles Transitional Holdings Inc. (NYSE:Q) insider Kevin C. Knightly sold 19,339 shares of the stock in a transaction on Friday, August 25th. The shares were sold at an average price of $99.51, for a total value of $1,924,423.89. Following the completion of the transaction, the insider now directly owns 40,650 shares in the company, valued at approximately $4,045,081.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Quintiles Transitional Holdings Inc. (NYSE Q) opened at 96.00 on Wednesday. The firm has a market cap of $20.79 billion, a P/E ratio of 278.26 and a beta of 0.64. The firm has a 50-day moving average of $91.06 and a 200 day moving average of $84.68. Quintiles Transitional Holdings Inc. has a 1-year low of $70.10 and a 1-year high of $99.95.
Quintiles Transitional Holdings (NYSE:Q) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.04. Quintiles Transitional Holdings had a net margin of 0.82% and a return on equity of 14.23%. The company had revenue of $1.97 billion during the quarter, compared to analysts’ expectations of $1.96 billion. During the same quarter in the prior year, the company posted $0.93 EPS. The business’s revenue was up 68.7% on a year-over-year basis. On average, analysts predict that Quintiles Transitional Holdings Inc. will post $4.58 EPS for the current year.
Quintiles Transitional Holdings declared that its Board of Directors has initiated a share repurchase plan on Wednesday, May 24th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 5.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.
Several research firms recently commented on Q. Barclays PLC reissued an “overweight” rating and issued a $98.00 target price (up previously from $90.00) on shares of Quintiles Transitional Holdings in a report on Monday, July 17th. William Blair raised Quintiles Transitional Holdings from a “market perform” rating to an “outperform” rating and increased their target price for the company from $70.10 to $93.42 in a report on Friday, August 4th. Jefferies Group LLC reissued a “hold” rating and issued a $94.00 target price on shares of Quintiles Transitional Holdings in a report on Friday, August 4th. Citigroup Inc. increased their target price on Quintiles Transitional Holdings from $96.00 to $97.00 and gave the company a “neutral” rating in a report on Monday, August 7th. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $92.00 target price (up previously from $87.00) on shares of Quintiles Transitional Holdings in a report on Friday, August 4th. Eleven investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Quintiles Transitional Holdings presently has a consensus rating of “Buy” and an average target price of $90.25.
Several institutional investors have recently made changes to their positions in the stock. Fiduciary Trust Co. purchased a new stake in shares of Quintiles Transitional Holdings during the second quarter worth about $105,000. Global X Management Co. LLC boosted its stake in shares of Quintiles Transitional Holdings by 30.8% in the first quarter. Global X Management Co. LLC now owns 1,469 shares of the medical research company’s stock worth $118,000 after buying an additional 346 shares during the period. GWM Advisors LLC purchased a new stake in shares of Quintiles Transitional Holdings during the second quarter worth about $122,000. Korea Investment CORP boosted its stake in shares of Quintiles Transitional Holdings by 142.5% in the second quarter. Korea Investment CORP now owns 1,370 shares of the medical research company’s stock worth $123,000 after buying an additional 805 shares during the period. Finally, IFP Advisors Inc boosted its stake in shares of Quintiles Transitional Holdings by 187.1% in the first quarter. IFP Advisors Inc now owns 1,774 shares of the medical research company’s stock worth $143,000 after buying an additional 1,156 shares during the period. Institutional investors own 91.36% of the company’s stock.
Quintiles Transitional Holdings Company Profile
Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.